Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

By L. Nikolaidis, S. Mankad, G. Sokos, G. Miske, Ankur G Shah, D. Elahi, R. Shannon. Circulation, 2004

910 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/0dc7750ba821df01163b1d1df8d11659f6b83edb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Endocrinology, Diabetes and Metabolism

Citations in the corpus

Cardiac Metabolism and Its Interactions with Contraction, Growth, and Survival of the Cardiomyocte (2013, result): “A study examining patients with an acute myocardial infarction and EF<40% after successful angioplasty treated with 72 hours of GLP-1 infusion demonstrated significantly greater EF associated with improved global and regional wall motion score indices compared with controls.(169)”
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. (2005, methodology): “More importantly, a recent clinical study (11) demonstrated that administration of GLP-1 improved left ventricular function in patients with acute myocardial infarction and left ventricular dysfunction.”
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. (2004, background): “GLP-1 improves severe left ventricular heart failure in humans suffering from a myocardial infarction (24).”
Diabetes and mortality following acute coronary syndromes. (2007, background): “For example, glucagon-like peptide-1 receptor agonists reduce both fasting and postprandial glucose concentrations and may even improve myocardial function following an acute MI, as demonstrated in a small, nonrandomized pilot study.(44) Such agents are worthy of investigation in large, longitudinal”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “…increase in myocardial glucose uptake and decreases in plasma norepinephrine and glucagon levels, despite similar insulin levels in the saline control group, suggesting that GLP-1 exerts myocardial metabolic effects that are independent of insulinotropic effects of GLP-1 (Nikolaidis et al., 2004a).”
Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways (2008, background): “Background—The glucagon-like peptide 1 receptor (GLP-1R) is believed to mediate glucoregulatory and cardiovascular effects of the incretin hormone GLP-1(7-36) (GLP-1), which is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) to GLP-1(9-36), a truncated metabolite generally thought to be inactive.”